Literature DB >> 17257684

Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death.

Ana M González-Vadillo1, Amparo Alvarez-Valdés, Victoria Moneo, Fernando Blanco, Raquel G Díaz, Amancio Carnero, Carmen Navarro-Ranninger.   

Abstract

The new trans-Pt complexes, derived from trans-[PtCl2(amine)(dimethylamine)] and trans-[PtCl2(OH)2(amine)(dimethylamine)], were synthesized and characterized studying the structure-activity relationship and testing their antiproliferative activity. Their evaluation as cytotoxic agents towards different cancer and normal cell lines is presented. These compounds are active in a panel of tumor cell lines at low micromolar range. Compounds seems to be more active in tumoral than in normal primary human cell lines. Cytotoxic activity is closely related to the amine ligand. Cyclohexylamine ligand was the most active among the amine-ligands tested. Cytotoxic activity correlates with an increase in annexin V positive cells indicating an apoptotic effect of the compounds. Mechanistically, the antitumor activity correlates with a blockade of the cell cycle in S phase and a complete abolishment of G2/M checkpoint arrest suggesting physical interaction of compound with DNA inhibiting S phase transition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257684     DOI: 10.1016/j.jinorgbio.2006.11.015

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  2 in total

1.  Nanostructured Pt(NH(3))(4)Cl(2)/SiO(2) for nanomedicine: catalytic degradation of DNA in cancer cells.

Authors:  Tessy López; Emma Ortíz Islas; Mayra A Alvarez Lemus; Richard Donald González
Journal:  Nano Rev       Date:  2011-01-13

2.  Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

Authors:  V Cepero; B García-Serrelde; V Moneo; F Blanco; A M González-Vadillo; A Alvarez-Valdés; C Navarro-Ranninger; A Carnero
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.